Uy Ear
Stock Analyst at Mizuho
(2.94)
# 1,539
Out of 4,944 analysts
65
Total ratings
41.03%
Success rate
11.71%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $23 → $24 | $25.45 | -5.70% | 12 | Aug 7, 2025 | |
| MBX MBX Biosciences | Initiates: Outperform | $38 | $12.53 | +203.27% | 1 | Aug 5, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Neutral | $40 → $14 | $18.80 | -25.53% | 8 | Jul 21, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $51 → $85 | $21.86 | +288.84% | 2 | May 15, 2025 | |
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $20 → $21 | $14.74 | +42.47% | 14 | Feb 26, 2025 | |
| QURE uniQure | Maintains: Neutral | $7 → $20 | $14.30 | +39.86% | 4 | Dec 19, 2024 | |
| RLMD Relmada Therapeutics | Downgrades: Neutral | $23 → $1 | $0.59 | +70.07% | 1 | Dec 5, 2024 | |
| ALKS Alkermes | Maintains: Outperform | $35 → $40 | $27.43 | +45.83% | 5 | Nov 13, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $40 | $11.26 | +255.24% | 1 | May 24, 2024 | |
| EOLS Evolus | Maintains: Buy | $20 → $23 | $6.40 | +259.38% | 3 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $116 → $140 | $128.89 | +8.62% | 10 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $172.78 | -76.85% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $1.33 | +651.88% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $1.03 | +191.26% | 2 | Mar 1, 2023 |
ACADIA Pharmaceuticals
Aug 7, 2025
Maintains: Neutral
Price Target: $23 → $24
Current: $25.45
Upside: -5.70%
MBX Biosciences
Aug 5, 2025
Initiates: Outperform
Price Target: $38
Current: $12.53
Upside: +203.27%
Sarepta Therapeutics
Jul 21, 2025
Downgrades: Neutral
Price Target: $40 → $14
Current: $18.80
Upside: -25.53%
Tectonic Therapeutic
May 15, 2025
Maintains: Outperform
Price Target: $51 → $85
Current: $21.86
Upside: +288.84%
Arcutis Biotherapeutics
Feb 26, 2025
Maintains: Outperform
Price Target: $20 → $21
Current: $14.74
Upside: +42.47%
uniQure
Dec 19, 2024
Maintains: Neutral
Price Target: $7 → $20
Current: $14.30
Upside: +39.86%
Relmada Therapeutics
Dec 5, 2024
Downgrades: Neutral
Price Target: $23 → $1
Current: $0.59
Upside: +70.07%
Alkermes
Nov 13, 2024
Maintains: Outperform
Price Target: $35 → $40
Current: $27.43
Upside: +45.83%
Cartesian Therapeutics
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $11.26
Upside: +255.24%
Evolus
Mar 8, 2024
Maintains: Buy
Price Target: $20 → $23
Current: $6.40
Upside: +259.38%
Feb 8, 2024
Maintains: Neutral
Price Target: $116 → $140
Current: $128.89
Upside: +8.62%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $172.78
Upside: -76.85%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $1.33
Upside: +651.88%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $1.03
Upside: +191.26%